Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9267789 | 0.89 | SLC22A2 (0.31) | — | |
| SCHEMBL23992270 | 0.89 | SLC22A2 (0.31) | — | |
| SCHEMBL12430402 | 0.84 | SLC22A2 (0.31) | — | |
| SCHEMBL24733209 | 0.84 | SLC22A2 (0.31) | — | |
| SCHEMBL6188004 | 0.81 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14410778 | 0.80 | — | — | |
| SCHEMBL25570309 | 0.80 | — | — | |
| SCHEMBL13543025 | 0.80 | — | — | |
| SCHEMBL13676318 | 0.79 | HRH3 (0.34) | — | |
| SCHEMBL2606742 | 0.79 | HRH3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893068-B2 | Macrolide compounds comprising 18,19-epoxytricosa-8,12,14-trien-11-olide derivatives; angiogenesis inhibitors; anticarcinogenic, antimetastasis, antiinflammatory, and antitumor agents; antihypoxic agents; endothelial growth factor suppressors; retinal neovascularization, diabetic retinopathy | MERCIAN CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7619100-B2 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7550503-B2 | Physiologically active substances | EISAI R& D MANAGEMENT CO., LTD. (JP) | 2009-06-23 | — | — | US | disclosed |
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | KOTAKE YOSHIHIKO | 2008-11-06 | — | — | US | disclosed |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7256178-B2 | Physiologically active substances | EISAI CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275059-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | CHRNB2 3577/4885CHRNB4 3590/4885CHRNA3 3694/4885 |
| US-20080255146-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | HIF1A, HIF1AN, VEGFA | CHRNB2 3577/4885CHRNB4 3590/4885CHRNA3 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.